Cobham wins Ground-Penetrating Radar awards
Cobham has announced that it has been awarded orders totalling over £13 million during the first quarter of 2012, for its Ground-Penetrating Radar (GPR) and support solutions. The company made the announcement 16 April 2012 in a statement.
The contracts have been received from a number of NATO customers, and are due for delivery in 2012 from the Cobham Antenna Systems site in Leatherhead, UK.
Fred Cahill, VP Cobham Antenna Systems, said of the contracts, ‘Cobham has been developing GPR technologies for many years and we continue to provide leading-edge Counter-Improvised Explosive Device (C-IED) capabilities for the most demanding military requirements.’
More from Land Warfare
-
![Canada places $231 million order for 85 Rheinmetall HX trucks]()
Canada places $231 million order for 85 Rheinmetall HX trucks
Canada has become the 21st country to have ordered or operate HX trucks, of which more than 10,000 platforms have been sold in 4x4, 6x6 and 8x8 configurations worldwide.
-
![Lockheed Martin to increase PAC-3 MSE production by 70%]()
Lockheed Martin to increase PAC-3 MSE production by 70%
The company manufactured 380 missiles in 2023 and plans to build 650 missiles per year from 2027.
-
![Latvia enters talks to buy GDELS ASCOD IFV]()
Latvia enters talks to buy GDELS ASCOD IFV
The ASCOD is in service with, or has been ordered by, five countries. In the UK it forms the basis of the British Army’s Ajax and for the US it is the chassis for the M10 Booker.
-
![Latvia orders more Patria 6x6 vehicles]()
Latvia orders more Patria 6x6 vehicles
The first Latvian-made Common Armoured Vehicle System (CAVS) 6x6 armoured personnel carrier was delivered to the Latvian National Armed Forces (NAF) in August, and more than 200 vehicles are expected to be delivered by 2029.
-
![Canadian tech firm makes promise to increase precision and longevity of weapons]()
Canadian tech firm makes promise to increase precision and longevity of weapons
Supplied by Paradigm Shift, EPVD technology has undergone trials with the US and Canadian services.
